Abstract: Epstein-Barr virus(EBV)is the first tumor-associated virus discovered in humans. It is closely related to the occurrence and development of nasopharyngeal carcinoma, gastric carcinoma, pulmonary lymphoepithelioma-like carcinoma, and several lymphomas. In EBV-positive solid tumors, the characteristics of the tumor immune microenvironment and the mechanism by which intrinsic innate immunity of epithelial cells plays a remodeling role have not been elucidated. Contemporary immune checkpoint inhibitor therapy has initially achieved good results in virus-associated tumors. In this article, we will focus on the review of the mechanism of EBV-infected cells, the changes of intrinsic immunity in EBV-positive solid tumors, and the progress of the application of immune checkpoint inhibitors in EBV-associated lung cancer and other tumors.